These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 16357184)

  • 1. BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors.
    Gibbs DD; Theti DS; Wood N; Green M; Raynaud F; Valenti M; Forster MD; Mitchell F; Bavetsias V; Henderson E; Jackman AL
    Cancer Res; 2005 Dec; 65(24):11721-8. PubMed ID: 16357184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective delivery of CB300638, a cyclopenta[g]quinazoline-based thymidylate synthase inhibitor into human tumor cell lines overexpressing the alpha-isoform of the folate receptor.
    Theti DS; Bavetsias V; Skelton LA; Titley J; Gibbs D; Jansen G; Jackman AL
    Cancer Res; 2003 Jul; 63(13):3612-8. PubMed ID: 12839949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
    Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
    Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antifolates targeted specifically to the folate receptor.
    Jackman AL; Theti DS; Gibbs DD
    Adv Drug Deliv Rev; 2004 Apr; 56(8):1111-25. PubMed ID: 15094210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo.
    Mauritz R; Peters GJ; Kathmann I; Teshale H; Noordhuis P; Comijn EM; Pinedo HM; Jansen G
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):937-48. PubMed ID: 18283461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.
    Jackman AL; Taylor GA; Gibson W; Kimbell R; Brown M; Calvert AH; Judson IR; Hughes LR
    Cancer Res; 1991 Oct; 51(20):5579-86. PubMed ID: 1913676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase.
    Jackman AL; Kimbell R; Aherne GW; Brunton L; Jansen G; Stephens TC; Smith MN; Wardleworth JM; Boyle FT
    Clin Cancer Res; 1997 Jun; 3(6):911-21. PubMed ID: 9815766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple membrane transport systems for the uptake of folate-based thymidylate synthase inhibitors.
    Jansen G; Schornagel JH; Westerhof GR; Rijksen G; Newell DR; Jackman AL
    Cancer Res; 1990 Dec; 50(23):7544-8. PubMed ID: 2253202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging pharmacodynamics of the alpha-folate receptor-targeted thymidylate synthase inhibitor BGC 945.
    Pillai RG; Forster M; Perumal M; Mitchell F; Leyton J; Aibgirhio FI; Golovko O; Jackman AL; Aboagye EO
    Cancer Res; 2008 May; 68(10):3827-34. PubMed ID: 18483267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase.
    Duch DS; Banks S; Dev IK; Dickerson SH; Ferone R; Heath LS; Humphreys J; Knick V; Pendergast W; Singer S
    Cancer Res; 1993 Feb; 53(4):810-8. PubMed ID: 8428362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of impact of the loss of constitutive folate receptor alpha expression, achieved by RNA Interference, on the activity of the new generation antifolate pemetrexed in HeLa cells.
    Chattopadhyay S; Wang Y; Zhao R; Goldman ID
    Clin Cancer Res; 2004 Dec; 10(23):7986-93. PubMed ID: 15585634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.
    van der Wilt CL; Backus HH; Smid K; Comijn L; Veerman G; Wouters D; Voorn DA; Priest DG; Bunni MA; Mitchell F; Jackman AL; Jansen G; Peters GJ
    Cancer Res; 2001 May; 61(9):3675-81. PubMed ID: 11325838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased thymidylate synthase in L1210 cells possessing acquired resistance to N10-propargyl-5,8-dideazafolic acid (CB3717): development, characterization, and cross-resistance studies.
    Jackman AL; Alison DL; Calvert AH; Harrap KR
    Cancer Res; 1986 Jun; 46(6):2810-5. PubMed ID: 2938731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.
    Jackman AL; Kelland LR; Kimbell R; Brown M; Gibson W; Aherne GW; Hardcastle A; Boyle FT
    Br J Cancer; 1995 May; 71(5):914-24. PubMed ID: 7537518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isostructural folate conjugates radiolabeled with the matched pair 99mTc/188Re: a potential strategy for diagnosis and therapy of folate receptor-positive tumors.
    Müller C; Schubiger PA; Schibli R
    Nucl Med Biol; 2007 Aug; 34(6):595-601. PubMed ID: 17707798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the antifolates pemetrexed and CB3717 on the tissue distribution of (99m)Tc-EC20 in xenografted and syngeneic tumor-bearing mice.
    Müller C; Reddy JA; Leamon CP; Schibli R
    Mol Pharm; 2010 Apr; 7(2):597-604. PubMed ID: 20199053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of methylenetetrahydrofolate depletion in methotrexate-mediated intracellular thymidylate synthesis inhibition in cultured L1210 cells.
    Bunni M; Doig MT; Donato H; Kesavan V; Priest DG
    Cancer Res; 1988 Jun; 48(12):3398-404. PubMed ID: 3370638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and preclinical evaluation of a folic acid derivative labeled with 18F for PET imaging of folate receptor-positive tumors.
    Bettio A; Honer M; Müller C; Brühlmeier M; Müller U; Schibli R; Groehn V; Schubiger AP; Ametamey SM
    J Nucl Med; 2006 Jul; 47(7):1153-60. PubMed ID: 16818950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of a folate transporter in HeLa cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier.
    Wang Y; Zhao R; Goldman ID
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6256-64. PubMed ID: 15448015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of alpha-folate receptor-mediated transport in the antitumor activity of antifolate drugs.
    Theti DS; Jackman AL
    Clin Cancer Res; 2004 Feb; 10(3):1080-9. PubMed ID: 14871988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.